AbCellera appoints Dr. Victor Sandor as independent director to board

AbCellera Biologics Inc.

Appointed Victor Sandor, M.D.C.M., to Board as independent director effective June 1, 2026.
Dr. Sandor brings oncology drug development expertise; previously CMO at Array BioPharma.
He secured approval of Braftovi and Mektovi at Array and contributed to Jakafi and Faslodex development.
Sandor currently serves on boards of ADC Therapeutics, Kymera Therapeutics, and Prelude Therapeutics.
Will not serve on any board committees initially; compensated per non-employee director policy.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Victor Sandor

Director

ABCL · AbCellera Biologics Inc.

Effective: 2026-06-01
Filed: June 5, 2026, 12:03 PM ET

On June 1, 2026, the Board of Directors (the "Board") of AbCellera Biologics Inc. (the "Company") appointed Victor Sandor as a new director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Victor Sandor was appointed as Director at AbCellera Biologics Inc..

Action: appointed
Role: Director

Exact text from the filing

On June 1, 2026, the Board of Directors (the "Board") of AbCellera Biologics Inc. (the "Company") appointed Victor Sandor as a new director.

View on SEC.gov

AbCellera Biologics Inc. filing history →

Source: SEC EDGAR

accession 0001703057-26-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.